403 related articles for article (PubMed ID: 25961924)
21. HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3.
Ruiz-Saenz A; Dreyer C; Campbell MR; Steri V; Gulizia N; Moasser MM
Cancer Res; 2018 Jul; 78(13):3645-3658. PubMed ID: 29760043
[TBL] [Abstract][Full Text] [Related]
22. Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.
Crafter C; Vincent JP; Tang E; Dudley P; James NH; Klinowska T; Davies BR
Int J Oncol; 2015 Aug; 47(2):446-54. PubMed ID: 26095475
[TBL] [Abstract][Full Text] [Related]
23. Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines.
Pino MS; Balsamo M; Di Modugno F; Mottolese M; Alessio M; Melucci E; Milella M; McConkey DJ; Philippar U; Gertler FB; Natali PG; Nisticò P
Clin Cancer Res; 2008 Aug; 14(15):4943-50. PubMed ID: 18676769
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of human ortholog of mammalian enabled (hMena) is associated with the expression of mutant p53 protein in human breast cancers.
Toyoda A; Yokota A; Saito T; Kawana H; Higashi M; Suzuki Y; Tanaka T; Kitagawa M; Harigaya K
Int J Oncol; 2011 Jan; 38(1):89-96. PubMed ID: 21109929
[TBL] [Abstract][Full Text] [Related]
25. Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin.
Campbell MR; Zhang H; Ziaee S; Ruiz-Saenz A; Gulizia N; Oeffinger J; Amin DN; Ahuja D; Moasser MM; Park CC
Breast Cancer Res Treat; 2016 Feb; 155(3):431-40. PubMed ID: 26860947
[TBL] [Abstract][Full Text] [Related]
26. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
27. Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer.
Di Modugno F; Di Carlo A; Spada S; Palermo B; D'Ambrosio L; D'Andrea D; Morello G; Belmonte B; Sperduti I; Balzano V; Gallo E; Melchionna R; Panetta M; Campo G; De Nicola F; Goeman F; Antoniani B; Carpano S; Frigè G; Warren S; Gallina F; Lambrechts D; Xiong J; Vincent BG; Wheeler N; Bortone DS; Cappuzzo F; Facciolo F; Tripodo C; Visca P; Nisticò P
EBioMedicine; 2024 Mar; 101():105003. PubMed ID: 38340557
[TBL] [Abstract][Full Text] [Related]
28. Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies.
Monteiro Ide P; Madureira P; de Vasconscelos A; Pozza DH; de Mello RA
Pharmacogenomics; 2015; 16(3):257-71. PubMed ID: 25712189
[TBL] [Abstract][Full Text] [Related]
29. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.
Chakrabarty A; Sánchez V; Kuba MG; Rinehart C; Arteaga CL
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2718-23. PubMed ID: 21368164
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
31. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
[TBL] [Abstract][Full Text] [Related]
32. Calpain4 is required for activation of HER2 in breast cancer cells exposed to trastuzumab and its suppression decreases survival and enhances response.
Kulkarni S; Saju L; Farver C; Tubbs R
Int J Cancer; 2012 Nov; 131(10):2420-32. PubMed ID: 22377768
[TBL] [Abstract][Full Text] [Related]
33. Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity.
Hanker AB; Brown BP; Meiler J; Marín A; Jayanthan HS; Ye D; Lin CC; Akamatsu H; Lee KM; Chatterjee S; Sudhan DR; Servetto A; Brewer MR; Koch JP; Sheehan JH; He J; Lalani AS; Arteaga CL
Cancer Cell; 2021 Aug; 39(8):1099-1114.e8. PubMed ID: 34171264
[TBL] [Abstract][Full Text] [Related]
34. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.
Serra V; Scaltriti M; Prudkin L; Eichhorn PJ; Ibrahim YH; Chandarlapaty S; Markman B; Rodriguez O; Guzman M; Rodriguez S; Gili M; Russillo M; Parra JL; Singh S; Arribas J; Rosen N; Baselga J
Oncogene; 2011 Jun; 30(22):2547-57. PubMed ID: 21278786
[TBL] [Abstract][Full Text] [Related]
35. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
Torka R; Pénzes K; Gusenbauer S; Baumann C; Szabadkai I; Őrfi L; Kéri G; Ullrich A
Neoplasia; 2014 Apr; 16(4):301-18. PubMed ID: 24862757
[TBL] [Abstract][Full Text] [Related]
36. Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers.
Young CD; Arteaga CL; Cook RS
Breast Cancer Res; 2015 Dec; 17():148. PubMed ID: 26637440
[TBL] [Abstract][Full Text] [Related]
37. Combined Blockade of Activating
Croessmann S; Formisano L; Kinch LN; Gonzalez-Ericsson PI; Sudhan DR; Nagy RJ; Mathew A; Bernicker EH; Cristofanilli M; He J; Cutler RE; Lalani AS; Miller VA; Lanman RB; Grishin NV; Arteaga CL
Clin Cancer Res; 2019 Jan; 25(1):277-289. PubMed ID: 30314968
[TBL] [Abstract][Full Text] [Related]
38. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.
Junttila TT; Akita RW; Parsons K; Fields C; Lewis Phillips GD; Friedman LS; Sampath D; Sliwkowski MX
Cancer Cell; 2009 May; 15(5):429-40. PubMed ID: 19411071
[TBL] [Abstract][Full Text] [Related]
39. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
[TBL] [Abstract][Full Text] [Related]
40. HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines.
Okita R; Mougiakakos D; Ando T; Mao Y; Sarhan D; Wennerberg E; Seliger B; Lundqvist A; Mimura K; Kiessling R
J Immunol; 2012 Mar; 188(5):2136-45. PubMed ID: 22301547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
